SCHEMBL5240645

SCHEMBL5240645

CCCCc1ccc(CNCCCNc2nsc3ccccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 8/20 0.42
S1PR3 Q99500 8/20 0.42
S1PR2 O95136 6/20 0.42
LPAR2 Q9HBW0 3/20 0.42
S1PR4 O95977 3/20 0.42
S1PR5 Q9H228 1/20 0.42
CASP6 P55212 1/20 0.41
SIGMAR1 Q99720 3/20 0.40
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
EPAS1 Q99814 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TLR8 Q9NR97 3/20 0.38
TLR7 Q9NYK1 3/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13202699 0.88 EPAS1 (0.43) CASP6EPAS1TLR8TLR7CYP1A2
SCHEMBL13202694 0.84 EPAS1 (0.52) EPAS1CYP1A2CYP2D6CYP2C19
SCHEMBL2977602 0.82 S1PR1 (0.47) S1PR1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL2978543 0.81 TMEM97 (0.53) SIGMAR1SMN1; SMN2CYP2D6CYP2C19
SCHEMBL2976630 0.81 LMNA (0.51) SMN1; SMN2
SCHEMBL13202695 0.81 EPAS1 (0.52) EPAS1
SCHEMBL3854234 0.81 SMN1; SMN2 (0.51) S1PR2CASP6EPAS1SMN1; SMN2
SCHEMBL13202686 0.80 THRA (0.46) S1PR1S1PR3S1PR2LPAR2S1PR4
SCHEMBL13202796 0.79 EPAS1 (0.56) EPAS1SMN1; SMN2CYP1A2CYP2D6CYP2C19
SCHEMBL13202726 0.79 ACHE (0.42) EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
EP-1853573-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION Rigel Pharmaceuticals, Inc. (US) 2007-11-14 EP disclosed
WO-2006091858-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2006-08-31 WO disclosed